USD
$0.00
(0.00%
)At Close (As of Sep 12, 2025)
$4.12B
Market Cap
-
P/E Ratio
-2.53
EPS
$47.40
52 Week High
$12.30
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | -$14K |
Total Revenue | $0 |
Cost Of Revenue | $14K |
Costof Goods And Services Sold | $14K |
Operating Income | -$225M |
Selling General And Administrative | $27M |
Research And Development | $108M |
Operating Expenses | $225M |
Investment Income Net | - |
Net Interest Income | $6M |
Interest Income | $6.2M |
Interest Expense | $223K |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $14K |
Income Before Tax | -$218M |
Income Tax Expense | -$9.3M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$209M |
Comprehensive Income Net Of Tax | - |
Ebit | -$218M |
Ebitda | -$218M |
Net Income | -$209M |
Field | Value (USD) |
---|---|
Total Assets | $451M |
Total Current Assets | $359M |
Cash And Cash Equivalents At Carrying Value | $352M |
Cash And Short Term Investments | $352M |
Inventory | - |
Current Net Receivables | - |
Total Non Current Assets | $92M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $69M |
Intangible Assets Excluding Goodwill | $69M |
Goodwill | $22M |
Investments | - |
Long Term Investments | - |
Short Term Investments | - |
Other Current Assets | $6.7M |
Other Non Current Assets | - |
Total Liabilities | $164M |
Total Current Liabilities | $67M |
Current Accounts Payable | $21M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $9.1M |
Total Non Current Liabilities | $96M |
Capital Lease Obligations | $1.4M |
Long Term Debt | - |
Current Long Term Debt | $8.4M |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $9.8M |
Other Current Liabilities | $37M |
Other Non Current Liabilities | $88M |
Total Shareholder Equity | $287M |
Treasury Stock | - |
Retained Earnings | -$257M |
Common Stock | - |
Common Stock Shares Outstanding | $105M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$100M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $14K |
Capital Expenditures | $43K |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | -$43K |
Cashflow From Financing | $378M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$209M |
Field | Value (USD) |
---|---|
Gross Profit | -$14K |
Total Revenue | $0 |
Cost Of Revenue | $14K |
Costof Goods And Services Sold | $14K |
Operating Income | -$225M |
Selling General And Administrative | $27M |
Research And Development | $108M |
Operating Expenses | $225M |
Investment Income Net | - |
Net Interest Income | $6M |
Interest Income | $6.2M |
Interest Expense | $223K |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $14K |
Income Before Tax | -$218M |
Income Tax Expense | -$9.3M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$209M |
Comprehensive Income Net Of Tax | - |
Ebit | -$218M |
Ebitda | -$218M |
Net Income | -$209M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. The company is headquartered in New York, New York.